 ALX Oncology Holdings Inc NASDAQ: ALXO released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastricgastroesophageal junction cancer patients receiving evorpacept plus Roche Holdings AGs OTC: RHHBY Herceptin trastuzumab, plus chemotherapy. 